Pharmaceutical-grade albumin: Impaired drug-binding capacity in vitro

BMC Clinical Pharmacology

Volumn 4, Issue , 2004, Pages

  Olsen, Harald ^a   Andersen, Anders ^a   Nordbö, Arve ^a   Kongsgaard, Ulf E ^a   Börmer, Ole P ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CHARCOAL; DIGITOXIN; LIGAND; N ACETYLTRYPTOPHAN; NAPROXEN; OCTANOIC ACID; SERUM ALBUMIN; STABILIZING AGENT; WARFARIN; ALBUMINOID; DRUG;

ADULT; ARTICLE; BINDING AFFINITY; BINDING SITE; COMPUTER MODEL; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG MANUFACTURE; DRUG SOLUTION; DRUG SPECIFICITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; MALE; QUANTITATIVE ANALYSIS; SERUM; STATISTICAL SIGNIFICANCE; ULTRAFILTRATION; COMPARATIVE STUDY; DRUG INDUSTRY; METABOLISM; PROTEIN BINDING;

ALBUMINS; DIGITOXIN; DRUG INDUSTRY; HUMANS; NAPROXEN; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; SERUM ALBUMIN; WARFARIN;

EID: 2942610651     PISSN: 14726904     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-4-4     Document Type: Article

References (25)

1. Kragh-Hansen U: Structure and ligand binding properties of human serum albumin. Dan Med Bull 1990, 37:57-84.
2. Vorum H: Reversible ligand binding to human serum albumin. Theoretical and clinical aspects. Dan Med Bull 1999, 46:379-399.
3. Tillement JP, Lhoste F, Giudicelli JF: Diseases and drug protein binding. Clin Pharmacokinet 1978, 3:144-154.
4. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. Cochrane Injuries Group Albumin Reviewers. BMJ 1998, 317:235-240.
5. Wilkes MM, Navickis RJ: Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001, 135:149-164.
6. Bormer OP, Amlie LM, Paus E, Kongsgard U: Automated albumin method underestimates pharmaceutical-grade albumin in vivo. Clin Chem 1999, 45:1082-1084.
7. Sudlow G, Birkett DJ, Wade DN: The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol 1975, 11:824-832.
8. Sjoholm I, Ekman B, Kober A, Ljungstedt-Pahlman I, Seiving B, Sjodin T: Binding of drugs to human serum albumin:XI. The specificity of three binding sites as studied with albumin immobilized in microparticles. Mol Pharmacol 1979, 16:767-777.
9. Borga O, Borga B: Serum protein binding of nonsteroidal antiinflammatory drugs: a comparative study. J Pharmacokinet Biopharm 1997, 25:63-77.
10. Mortensen A, Jensen EB, Petersen PB, Husted S, Andreasen F: The determination of naproxen by spectrofluorometry and its binding to serum proteins. Acta Pharmacol Toxicol (Copenh) 1979, 44:277-283.
11. Wong YW, Davis PJ: Analysis of warfarin and its metabolites by reversed-phase ion-pair liquid chromatography with fluorescence detection. J Chromatogr 1989, 469:281-291.
12. Plum J, Daldrup T: Detection of digoxin, digitoxin, their cardioactive metabolites and derivatives by high-performance liquid chromatography and high-performance liquid chromatography-radioimmunoassay. J Chromatogr 1986, 377:221-231.
13. Dasgupta A, Vega AE, Wells A, Datta P: Sensitive methods for determination of free digitoxin concentration using digitoxin immunoassays: demonstration of elevated free digitoxin concentration caused by digitoxin-phenytoin interaction by applying these new techniques. Ther Drug Monit 1999, 21:625-630.
14. Riley CM, Tomlinson E, Jefferies TM, Redfern PH: Surfactant ionpair high-performance liquid chromatography of tryptophan and some of its metabolites in biological fluids. J Chromatogr 1979, 162:153-161.
15. Herve C, Beyne P, Jamault H, Delacoux E: Determination of tryptophan and its kynurenine pathway metabolites in human serum by high-performance liquid chromatography with simultaneous ultraviolet and fluorimetric detection. J Chromatogr B Biomed Appl 1996, 675:157-161.
16. Nelis HJ, Lefevere MF, Baert E, D'Hoore W, De Leenheer AP: Chromatographic determination of N-acetyl-DL-tryptophan and octanoic acid in human albumin solutions. J Chromatogr 1985, 333:381-387.
17. Scatchard G: The attraction of proteins for small molecules and ions. Ann N Y Acad Sci 1949, 51:660-672.
18. Goldstein A, Aronow L, Kalman SM: Molecular Mechanisms of Drug Action. In Principles of Drug Action New York: Jonh Wiley & Sons, Inc; 1974:1-127.
19. Brors O, Fremstad D, Poulsson C: The affinity of human serum albumin for [3H]-digitoxin is dependent on albumin concentration. Pharmacol Toxicol 1993, 72:310-313.
20. Kragh-Hansen U: Octanoate binding to the indole- and benzodiazepine-binding region of human serum albumin. Biochem J 1991, 273:641-644.
21. Lagrange F, Penhourcq F, Matoga M, Bannwarth B: Binding of ketoprofen enantiomers in various human albumin preparations. J Pharm Biomed Anal 2000, 23:793-802.
22. Matejtschuk P, Dash CH, Gascoigne EW: Production of human albumin solution: a continually developing colloid. Br J Anaesth 2000, 85:887-895.
23. Pacifici GM, Viani A: Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences. Clin Pharmacokinet 1992, 23:449-468.
24. Kragh-Hansen U: Relations between high-affinity binding sites of markers for binding regions on human serum albumin. Biochem J 1985, 225:629-638.
25. O'Reilly RA: The binding of sodium warfarin to plasma albumin and its displacement by phenylbutazone. Ann N Y Acad Sci 1973, 226:293-308.